ARTICLE | Company News
Ascepion, Debiopharm deal
June 25, 2012 7:00 AM UTC
Ascepion granted Debiopharm exclusive, worldwide rights to develop and commercialize Debio 1144 (formerly ASP-08126). The oral small molecule that inhibits several tyrosine kinases is in preclinical...